Structure of the aspartic protease plasmepsin 4 from the malarial parasite Plasmodium malariae bound to an allophenylnorstatine-based inhibitor.

The malarial parasite continues to be one of the leading causes of death in many developing countries. With the development of resistance to the currently available treatments, the discovery of new therapeutics is imperative. Currently, the plasmepsin enzymes found in the food vacuole of the parasite are a chief target for drug development. Allophenylnorstatine-based compounds originally designed to inhibit HIV-1 protease have shown efficacy against all four plasmepsin enzymes found in the food vacuole of Plasmodium falciparum. In this study, the first crystal structure of P. malariae plasmepsin 4 (PmPM4) bound to the allophenylnorstatine-based compound KNI-764 is described at 3.3 Angstroms resolution. The PmPM4-inhibitor complex crystallized in the orthorhombic space group P2(1)2(1)2, with unit-cell parameters a = 95.9, b = 112.6, c = 90.4 Angstroms, with two molecules in the asymmetric unit related by a non-crystallographic symmetry operator. The structure was refined to a final R factor of 24.7%. The complex showed the inhibitor in an unexpected binding orientation with allophenylnorstatine occupying the S1' pocket. The P2 group was found outside the S2 pocket, wedged between the flap and a juxtaposed loop. Inhibition analysis of PmPM4 also suggests the potential for allophenylnorstatine-based compounds to be effective against all species of malaria infecting humans and for the future development of a broad-based inhibitor.

[1]  S. Gulnik,et al.  Novel uncomplexed and complexed structures of plasmepsin II, an aspartic protease from Plasmodium falciparum. , 2003, Journal of molecular biology.

[2]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[3]  I D Kuntz,et al.  Potent, low-molecular-weight non-peptide inhibitors of malarial aspartyl protease plasmepsin II. , 1999, Journal of medicinal chemistry.

[4]  A. Kiriyama,et al.  Pharmacokinetic study of a tripeptide HIV‐1 protease inhibitor, KNI‐174, in rats after intravenous and intraduodenal administrations , 1993, Biopharmaceutics & drug disposition.

[5]  Y. Kiso,et al.  Small dipeptide-based HIV protease inhibitors containing the hydroxymethylcarbonyl isostere as an ideal transition-state mimic. , 1999, Biopolymers.

[6]  E A Merritt,et al.  Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.

[7]  E. Freire,et al.  Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases , 2004, Biological chemistry.

[8]  Y. Kiso,et al.  KNI-102, a novel tripeptide HIV protease inhibitor containing allophenylnorstatine as a transition-state mimic. , 1991, Chemical & pharmaceutical bulletin.

[9]  J. Dame,et al.  Plasmodium falciparum, P. vivax, and P. malariae: a comparison of the active site properties of plasmepsins cloned and expressed from three different species of the malaria parasite. , 1997, Experimental parasitology.

[10]  J. Dame,et al.  Active-site specificity of digestive aspartic peptidases from the four species of Plasmodium that infect humans using chromogenic combinatorial peptide libraries. , 2005, Biochemistry.

[11]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[12]  P. Rosenthal,et al.  Plasmodium falciparum: effects of proteinase inhibitors on globin hydrolysis by cultured malaria parasites. , 1995, Experimental parasitology.

[13]  Robert M Stroud,et al.  Anisotropic dynamics of the JE-2147-HIV protease complex: drug resistance and thermodynamic binding mode examined in a 1.09 A structure. , 2002, Biochemistry.

[14]  E. Freire,et al.  Identification and characterization of allophenylnorstatine-based inhibitors of plasmepsin II, an antimalarial target. , 2002, Biochemistry.

[15]  H Enomoto,et al.  Kynostatin (KNI)-227 and -272, highly potent anti-HIV agents: conformationally constrained tripeptide inhibitors of HIV protease containing allophenylnorstatine. , 1992, Chemical & pharmaceutical bulletin.

[16]  Jun Liu,et al.  High-affinity inhibition of a family of Plasmodium falciparum proteases by a designed adaptive inhibitor. , 2003, Biochemistry.

[17]  D. Goldberg,et al.  Aspartic proteases of Plasmodium falciparum and other parasitic protozoa as drug targets. , 2001, Trends in parasitology.

[18]  L. Prade,et al.  X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor* , 2005, Journal of Biological Chemistry.

[19]  I. Gluzman,et al.  Molecular characterization and inhibition of a Plasmodium falciparum aspartic hemoglobinase. , 1994, The EMBO journal.

[20]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[21]  D. Sullivan,et al.  Hemoglobin metabolism in the malaria parasite Plasmodium falciparum. , 1997, Annual review of microbiology.

[22]  J. Dame,et al.  Genetic Disruption of the Plasmodium falciparum Digestive Vacuole Plasmepsins Demonstrates Their Functional Redundancy* , 2004, Journal of Biological Chemistry.

[23]  E. Freire,et al.  The integration of genomic and structural information in the development of high affinity plasmepsin inhibitors. , 2002, International journal for parasitology.

[24]  J. Dame,et al.  Structural insights into the activation of P. vivax plasmepsin. , 2003, Journal of molecular biology.